PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.44 Billion KRW | 31.94% |
| 2022 | 68.21 Billion KRW | 37.81% |
| 2021 | 49.49 Billion KRW | 45.25% |
| 2020 | 34.07 Billion KRW | 30.32% |
| 2019 | 26.14 Billion KRW | 1.85% |
| 2018 | 25.67 Billion KRW | 23.99% |
| 2017 | 20.7 Billion KRW | 27.64% |
| 2016 | 16.22 Billion KRW | 76.02% |
| 2015 | 9.21 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 26.46 Billion KRW | 14.48% |
| 2024 Q1 | 23 Billion KRW | -14.54% |
| 2023 Q4 | 26.92 Billion KRW | 27.62% |
| 2023 Q2 | 24.23 Billion KRW | 36.61% |
| 2023 Q1 | 17.74 Billion KRW | -16.03% |
| 2023 Q3 | 21.09 Billion KRW | -12.98% |
| 2023 FY | 89.99 Billion KRW | 31.94% |
| 2022 Q1 | 15.07 Billion KRW | -0.3% |
| 2022 FY | 68.21 Billion KRW | 37.81% |
| 2022 Q4 | 21.13 Billion KRW | 37.13% |
| 2022 Q2 | 16.6 Billion KRW | 10.15% |
| 2022 Q3 | 15.4 Billion KRW | -7.18% |
| 2021 Q1 | 10.68 Billion KRW | 21.8% |
| 2021 Q2 | 11.83 Billion KRW | 10.71% |
| 2021 Q3 | 11.86 Billion KRW | 0.28% |
| 2021 Q4 | 15.11 Billion KRW | 27.41% |
| 2021 FY | 49.49 Billion KRW | 45.25% |
| 2020 Q2 | 5.66 Billion KRW | -31.81% |
| 2020 Q3 | 10.92 Billion KRW | 92.97% |
| 2020 Q4 | 8.77 Billion KRW | -19.71% |
| 2020 FY | 34.07 Billion KRW | 30.32% |
| 2020 Q1 | 8.3 Billion KRW | -17.79% |
| 2019 Q2 | 7.44 Billion KRW | 7.41% |
| 2019 FY | 26.14 Billion KRW | 1.85% |
| 2019 Q4 | 10.1 Billion KRW | 44.88% |
| 2019 Q3 | 6.97 Billion KRW | -6.29% |
| 2019 Q1 | 6.92 Billion KRW | 69.44% |
| 2018 FY | 25.67 Billion KRW | 23.99% |
| 2018 Q4 | 4.08 Billion KRW | -48.71% |
| 2018 Q3 | 7.97 Billion KRW | -2.69% |
| 2018 Q1 | 5.32 Billion KRW | -53.32% |
| 2018 Q2 | 8.19 Billion KRW | 53.69% |
| 2017 Q3 | 3.35 Billion KRW | -26.77% |
| 2017 Q2 | 4.57 Billion KRW | 11.14% |
| 2017 Q1 | 4.11 Billion KRW | -52.6% |
| 2017 FY | 20.7 Billion KRW | 27.64% |
| 2017 Q4 | 11.41 Billion KRW | 240.47% |
| 2016 Q4 | 8.69 Billion KRW | 441.65% |
| 2016 Q1 | 3.5 Billion KRW | 11.32% |
| 2016 FY | 16.22 Billion KRW | 76.02% |
| 2016 Q3 | 1.6 Billion KRW | -26.65% |
| 2016 Q2 | 2.18 Billion KRW | -37.56% |
| 2015 FY | 9.21 Billion KRW | 0.0% |
| 2015 Q4 | 3.14 Billion KRW | 55.59% |
| 2015 Q3 | 2.02 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 18.68% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -1039.982% |
| BINEX Co., Ltd. | 55.67 Billion KRW | -60.646% |
| Bioneer Corporation | 204.55 Billion KRW | 56.276% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -1055.54% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | -36.938% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -176.309% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -139.356% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 68.72% |
| Medy-Tox Inc. | 110.88 Billion KRW | 19.339% |
| Peptron, Inc. | 16.65 Billion KRW | -436.971% |
| Amicogen, Inc. | 52.82 Billion KRW | -69.321% |
| Genexine, Inc. | 41.62 Billion KRW | -114.856% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -453.249% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 9.307% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -118.493% |
| SillaJen, Inc. | 5.11 Billion KRW | -1649.543% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -248.503% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -153.736% |
| Genomictree Inc. | 16.26 Billion KRW | -449.902% |
| MedPacto, Inc. | 26.91 Billion KRW | -232.255% |
| D&D Pharmatech | 32.16 Billion KRW | -178.084% |
| EASY BIO,Inc. | 29.67 Billion KRW | -201.433% |
| GI Innovation, Inc. | 57.59 Billion KRW | -55.298% |